New diabetes injection tested against standard treatments in major chinese study
NCT ID NCT07307235
Summary
This study compares a newer combination diabetes injection (iGlarLixi) against standard insulin treatments in adults whose type 2 diabetes isn't well controlled with pills alone. About 1,300 participants across China will receive either the combination injection or standard insulin therapy for 24 weeks. Researchers will measure which approach better lowers blood sugar levels while minimizing side effects like weight gain and low blood sugar episodes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.